inflammatory bowel diseases

Tert-butyl 4-[[1-[(4-chlorophenyl)methyl]-3-hydroxy-2-oxopyridin-4-yl]methyl]piperazine-1-carboxylate inhibit of human recombinant EGLN-1 as substrate after 20 mins by mass spectrophotometric analysis.

Elubrixin (SB-656933) inhibits neutrophil CD11b upregulation (IC50 of 260.7 nM) and shape change (IC50 of 310.5 nM). Elubrixin can be used for inflammatory diseases such as inflammatory bowel disease and airway inflammation. Elubrixin is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist.

Vercirnon (Traficet-EN) is a selective and potent antagonist of CCR9 (IC50: 10 nM). It is also used in the research of inflammatory bowel diseases.

L-Homocysteine is a biological thiol involved in various diseases and pathological conditions. It is a marker for atherosclerosis and can exacerbate intestinal inflammation in inflammatory bowel disease (IBD) by promoting the expression of 5-LOX and COX-2, making it suitable for inducing vascular endothelial inflammation models.

4-Iodobutyl benzoate is structurally related to bicyclic heterocyclic compounds such as indole and indoline. It functions as a metabolite of drug amides and is utilized in the treatment of inflammatory bowel disease, degenerative diseases, and intestinal disorders. 4-Iodobutyl benzoate inhibits the activity of proteolytic enzymes by binding to their active sites.

STAT4-IN-1 is a STAT4 inhibitor with a Ki of 0.35 μM. It holds promise for research into autoimmune diseases, including inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, and diabetes.

SCH-900875 is an orally active, brain-penetrant, and selective inhibitor of the CXCR3 receptor, demonstrating significant selectivity towards CXCR1 and CXCR2 receptors as well. By binding to CXCR3, SCH-900875 blocks the ligands CXCL9, CXCL10, and CXCL11, thereby inhibiting downstream G protein and β-arrestin signaling pathways and reducing inflammation cell migration. This compound holds potential for research into autoimmune diseases (such as rheumatoid arthritis and multiple sclerosis) and inflammatory conditions (such as psoriasis and inflammatory bowel disease).

2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide (GDC046), a potent lead analog, has good kinase selectivity, physicochemical properties and pharmacokinetic profile.

Elubrixin tosylate (SB-656933 tosylate) is a high-potency, selective, competitive, and reversible CXCR2 and IL-8 receptor antagonist. It effectively inhibits neutrophil CD11b upregulation (IC50 of 260.7 nM) and shape change (IC50 of 310.5 nM). This compound holds promise for studying inflammatory diseases, including inflammatory bowel disease and airway inflammation.

TCJL37, a potent, selective, and orally bioavailable inhibitor of TYK2, exhibits a K i value of 1.6 nM. It is useful for researching inflammatory bowel diseases (IBD) [1].

CCR6 antagonist 1, a chemical compound acting as a CCR6 antagonist, effectively inhibits the CCL20 CCR6 axis. Its utility lies in research focused on autoimmune-mediated inflammatory diseases, including inflammatory bowel diseases (IBDs).

Mercaptoethylguanidine (MEG) dihydrobromide is a selective inducible nitric oxide synthase inhibitor and peroxynitrite scavenger with potential for inflammatory bowel diseases research.

Izilendustat (hydrochloride) is a potent inhibitor of prolyl hydroxylase that stabilizes hypoxia-inducible factor-1 alpha (HIF-1α) and hypoxia-inducible factor-2 (HIF-2), with potential applications in HIF-1α-related diseases, including peripheral vascular disease (PVD), heart failure, coronary artery disease (CAD), ischaemia, anaemia, colitis, and other inflammatory bowel diseases.

LON63114, also known as FFA2-Agonist-1 is a selective orthosteric agonist of human FFA2. FFA2-Agonist-1 is potentially useful in the treatment of gastrointestinal disorders and inflammatory bowel diseases. LON63114 was reported in WO2011076732. This product has no formal name at the moment. For the convenience of communication, a temporal code name was therefore proposed according to MedKoo Chemical Nomenclature (see web page: https: www.medkoo.com page naming).

Firsekibart is an immunoglobulin G4-λ2 monoclonal antibody that targets human interleukin 1β (IL-1β). It holds potential for use in treating inflammation-related diseases, such as rheumatoid arthritis and inflammatory bowel disease.

d-GLP-2 E33A is an agonist of the glucagon-like peptide 2 receptor (GLP-2R) with an EC50 of 414 nM. It activates GLP-2R and enhances the phosphorylation of AKT without stimulating GLP-1R. d-GLP-2 E33A is used for research in conditions such as malabsorption and inflammatory bowel diseases.

Amilo-5MER (5-MP) (TFA) is an orally active and selective inhibitor of serum amyloid A (SAA). It specifically inhibits the release of pro-inflammatory cytokines IL-6 and IL-1β in SAA-activated cells. Amilo-5MER (TFA) helps reduce chronic inflammation, alleviating symptoms associated with rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and multiple sclerosis (MS). It holds potential for research into autoimmune and chronic inflammatory diseases.

Amilo-5MER (5-MP) is an orally active and selective inhibitor of serum amyloid A (SAA). It specifically suppresses the release of pro-inflammatory cytokines IL-6 and IL-1β in SAA-activated cells. Amilo-5MER reduces chronic inflammation and alleviates symptoms of diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and multiple sclerosis (MS). It holds potential for research in autoimmune and chronic inflammatory diseases.